Balancing the Gut. Protecting the Liver.
LiverDophilus® is an evidence-based probiotic concept developed in collaboration with:
Institute for Biological Research “Siniša Stanković” and
Institute for Molecular Genetics and Genetic Engineering (IMGGI).
The formulation is centered around the patented strain Lactobacillus helveticus, a scientifically characterized microorganism with documented potential to support liver health via modulation of the gut–liver axis.
The strain has been investigated in preclinical models for its ability to reduce liver fat accumulation, influence metabolic pathways associated with steatosis, modulate systemic and hepatic inflammatory signaling, and promote intestinal barrier integrity. These functional properties align with the growing scientific interest in targeted probiotics for metabolic dysfunction-associated steatotic liver disease (MASLD).
The World Gastroenterology Organisation (WGO) Global Guidelines on Probiotics and Prebiotics (2023) highlight specific probiotic strains as beneficial for MASLD management (Level III evidence), supporting the relevance of the BGRA43 strain.
LiverDophilus® is a patented, safe, and scientifically substantiated solution designed for the expanding liver health segment, offering a biological, non-invasive approach to MASLD-related challenges.
LiverDophilus® is powered by the patented Lactobacillus helveticus BGRA43 strain, extensively characterized for its technological robustness and functional potential in metabolic and liver-related applications.
Documented functional activities include:
• Reduction of high-fat diet–induced hepatic steatosis in preclinical models
• Preservation of hepatocyte morphology under metabolic stress
• Modulation of inflammatory cytokine signaling pathways
• Normalization of gut microbial composition
• Enhancement of intestinal barrier function
LiverDophilus® meets the highest quality standards for probiotic raw materials.
• Strain identity verified
• High viability and stability under standard storage conditions
• Manufactured according to internationally recognized safety and quality principles
• Suitable for incorporation into a wide range of finished product formats
LiverDophilus® is powered by the patented Lactobacillus helveticus BGRA43 strain, extensively characterized for its technological robustness and functional potential in metabolic and liver-related applications.
Documented functional activities include:
• Reduction of high-fat diet–induced hepatic steatosis in preclinical models
• Preservation of hepatocyte morphology under metabolic stress
• Modulation of inflammatory cytokine signaling pathways
• Normalization of gut microbial composition
• Enhancement of intestinal barrier function
LiverDophilus® meets the highest quality standards for probiotic raw materials.
• Strain identity verified
• High viability and stability under standard storage conditions
• Manufactured according to internationally recognized safety and quality principles
• Suitable for incorporation into a wide range of finished product formats
The strain can be formulated as a standalone ingredient or combined with complementary components such as konjac mannan (plant-based fiber) to enhance synergistic gut–liver axis benefits.
LiverDophilus® also performs well in fermented dairy matrices such as yogurt and kefir, as well as other functional foods and beverages.
